Biofil Chemicals & Pharmaceuticals Ltd. (BSE: 524396) is an Indore, Madhya Pradesh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹51 Cr, it ranks #3,774 by market cap among the 6,197 Indian listed companies on FinBizNet, and #73 of 86 in Medicinal Chemicals and Botanical Products. At ₹31.30 (as of 16 Nov 2026), the share price is 32.5% below its 52-week high of ₹46.34 and 22.3% above its 52-week low of ₹25.60. The share price is down 18.9% over one year and down 1.3% over three months.
| Current Price | ₹31.30 |
|---|---|
| Market Cap | ₹51 Cr |
| BSE Code | 524396 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 18.3 |
| Return on Equity | 13.83% |
| Return on Assets | 0.66% |
| 52-Week Range | ₹25.60 – ₹46.34 |
| 1-Year Price Change | -18.9% |
| 3-Month Price Change | -1.3% |
| Beta (1Y) | 0.4 |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.biofilgroup.net |
| Revenue | ₹2 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 7.2% |
| EPS (Basic) | ₹0.07 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Biofil Chemicals & Pharmaceuticals Ltd. reported revenue of ₹2 Cr in Q2 FY27, down 87.7% from ₹14 Cr in Q2 FY26 and down 86.5% from ₹12 Cr in Q1 FY27. It posted a net profit of ₹0 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26 (up 50.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1 Cr (Q3 FY26) to ₹14 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2 Cr | ₹0 Cr | 7.2% |
| Q1 FY27 | ₹12 Cr | ₹0 Cr | 0.9% |
| Q4 FY26 | ₹8 Cr | ₹0 Cr | 2.8% |
| Q3 FY26 | ₹1 Cr | ₹0 Cr | 9.3% |
| Q2 FY26 | ₹14 Cr | ₹0 Cr | 0.6% |
| Q1 FY26 | ₹6 Cr | ₹2 Cr | 37.5% |
| Q4 FY25 | ₹8 Cr | ₹0 Cr | 2.4% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 46.79% of Biofil Chemicals & Pharmaceuticals Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 68.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and packaging solutions. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.
1. Pharma Division-This segment manufactures and sells pharmaceutical products. 2. Chemicals Division-This segment manufactures and sells chemicals. 3. Other-0 4. Segment Adjustment-0
1. Pharma Division-66.8% 2. Chemical Division-33.2%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹51 Cr | 18.3 | 13.83% | ₹2 Cr | -18.9% |
Listed by market capitalisation. Ratios are shown for context only.
Biofil Chemicals & Pharmaceuticals Ltd. is trading at ₹31.30, with a market capitalisation of ₹51 Cr.
Biofil Chemicals & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Biofil Chemicals & Pharmaceuticals Ltd. has a P/E of 18.3 and a return on equity of 13.83%.
Biofil Chemicals & Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524396.
Biofil Chemicals & Pharmaceuticals Ltd.'s share price is down 18.9% over one year and down 1.3% over three months. Its 52-week range is ₹25.60 to ₹46.34.
In Q2 FY27, Biofil Chemicals & Pharmaceuticals Ltd. reported revenue of ₹2 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.07 (standalone, parsed from the company's exchange filing).
Biofil Chemicals & Pharmaceuticals Ltd. reported revenue of ₹2 Cr in Q2 FY27, down 87.7% from ₹14 Cr in Q2 FY26 and down 86.5% from ₹12 Cr in Q1 FY27.
Promoters held 46.79% of Biofil Chemicals & Pharmaceuticals Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.